8-K: Biohaven's Troriluzole NDA for Spinocerebellar Ataxia Faces FDA Delay

The FDA has extended the PDUFA date for Biohaven's troriluzole NDA for spinocerebellar ataxia by three months, and plans to hold an advisory committee meeting to discuss the application.

Summary

• Biohaven Ltd. announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for troriluzole's new drug application (NDA) by three months.
• The extension is to allow the FDA more time to fully review Biohaven's recent submissions related to information requests.
• The FDA also plans to hold an advisory committee meeting to discuss the application, but a date has not yet been scheduled.
• The FDA's decision regarding the NDA is now expected in the fourth quarter of 2025.
• Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.
• If approved, troriluzole would be the first and only FDA-approved treatment for spinocerebellar ataxia (SCA).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the PDUFA date extension is a setback, the potential for troriluzole to be the first approved treatment for SCA and the favorable clinical data provide some optimism.

Positives

• Troriluzole has the potential to be the first and only FDA-approved treatment for SCA, a rare and life-threatening neurodegenerative disease.
• Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.
• Clinical data presented in the NDA show a highly favorable benefit-risk profile with troriluzole, a once-daily oral pill, slowing disease progression by 50-70%, as measured by the f-SARA scale, and reducing the risk of falls.
• The mid cycle review concluded that there were no previously unidentified major safety concerns, and it does not appear a Risk Evaluation and Mitigation Strategy (REMS) is needed.

Negatives

• The FDA has extended the PDUFA date for the troriluzole NDA by three months, delaying the potential approval of the drug.

Risks

• The FDA may not ultimately approve troriluzole for the treatment of SCA.
• The advisory committee may not recommend approval of troriluzole.
• The commercialization of troriluzole may be subject to regulatory requirements and competition from other therapies.

Future Outlook

The FDA's decision regarding the NDA for troriluzole is now expected in the fourth quarter of 2025.

Management Comments

• 'SCA is a devastating neurodegenerative disease that has affected generations of families and has no current approved therapy,' stated Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven.
• 'We are committed to bringing the first treatment to patients and families affected by SCA.'
• 'We look forward to a meeting with the advisory committee to discuss troriluzole's potential to improve the lives of individuals with SCA.'

Industry Context

The announcement highlights the ongoing efforts to develop treatments for rare neurodegenerative diseases like SCA, where there are currently no FDA-approved therapies. The potential approval of troriluzole would represent a significant advancement in the treatment of this condition.

Comparison to Industry Standards

• Currently, there are no FDA-approved treatments for SCA, making troriluzole a potential first-in-class therapy.
• Other companies are also developing treatments for SCA, but troriluzole is one of the most advanced programs in clinical development.
• The 50-70% slowing of disease progression, as measured by the f-SARA scale, is a clinically meaningful benefit that could significantly improve the lives of patients with SCA.

Stakeholder Impact

• Patients and families affected by SCA could benefit from the potential approval of troriluzole.
• Biohaven shareholders may be impacted by the delay in the PDUFA date and the uncertainty surrounding the FDA's decision.

Next Steps

• The FDA will hold an advisory committee meeting to discuss the application.
• The FDA will make a decision regarding the NDA in the fourth quarter of 2025.

Key Dates

Keywords

troriluzole, spinocerebellar ataxia, SCA, FDA, PDUFA, NDA, Biohaven, neurology, orphan drug, priority review